Daily Edition · Page 1

THE DAILY INDEX

Technology, AI, software, security, crypto and business

Across today’s newsletters

Today’s Index

WHY AIRBNB MOVED AWAY FROM A MONOLITHIC ARCHITECTURE

Airbnb's migration from a monolithic Ruby on Rails architecture to a service-oriented architecture (SOA) in 2018 was driven by the need for improved maintainability and reduced single points of failure. The company outlined four key lessons learned during this transition: invest in shared infrastructure early, simplify service dependencies, centralize data hydration, and separate UI logic from backend logic. This article discusses the transition and compares Airbnb's architectural choices with those of other tech giants like Meta, Google, and Uber.

BITCOIN PLUNGES BELOW $50,000, ETHER UNDER $2,200 AMID JUMP CRYPTO MOVES, US ELECTION UNCERTAINTY

Bitcoin hit its lowest price since February, and the rest of the market saw greater than 20% decreases in one of the biggest selloffs since FTX. Investors are reacting to several events, including Jump Crypto liquidating hundreds of millions of dollars of assets, the increasing chances of a Kamala Harris presidency, and a sharp decline in Japan's stock market. There are also fears about an impending recession, and ETHE investors are selling their positions in the Grayscale trust.

A PRIMER ON THE CURRENT STATE OF LONGEVITY RESEARCH

This article takes a look at how far the field of aging research has progressed since 2021. Nothing particularly useful has come from sirtuin-focused therapies and this is unlikely to change. The increase in longevity-focused research institutions/grant programs/startups hasn't led to much progress, but it's still very early. Cellar reprogramming has shown promise in animal studies, but no therapies have reached clinical trials yet. There's still a lot we don't know about biological clocks - everyday consumers should probably avoid getting their biological age tested. While epigenetic clocks seem to be useful, their interpretation is a bit complicated.

PATH TO PRECISION: TARGETED CANCER DRUGS GO FROM TABLE TO TRIALS TO BEDSIDE

There are now many targeted therapies and new techniques in the pipeline for treating various types of cancer. This article looks at the history of targeted cancer treatments to see how far the science has come. It took many preclinical studies, genetic sequencing advances, and other breakthroughs to get where we are now. The success of current treatments would not have been possible without all of the research legwork and basic science over the past few decades.

TLDR IndexPage 1